These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 9764927)

  • 1. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
    McKillop D; Wild MJ; Butters CJ; Simcock C
    Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
    Grimm SW; Dyroff MC
    Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
    von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
    J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.
    Crewe HK; Ellis SW; Lennard MS; Tucker GT
    Biochem Pharmacol; 1997 Jan; 53(2):171-8. PubMed ID: 9037249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X; Wang JS; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
    Eagling VA; Tjia JF; Back DJ
    Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
    Baldwin SJ; Clarke SE; Chenery RJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):424-32. PubMed ID: 10510156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
    Hyland R; Roe EG; Jones BC; Smith DA
    Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activity in Human Liver Microsomes.
    AlRabiah H; Ahad A; Mostafa GAE; Al-Jenoobi FI
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):707-713. PubMed ID: 29744741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4.
    Chesné C; Guyomard C; Guillouzo A; Schmid J; Ludwig E; Sauter T
    Xenobiotica; 1998 Jan; 28(1):1-13. PubMed ID: 9493314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen.
    Miners JO; Coulter S; Tukey RH; Veronese ME; Birkett DJ
    Biochem Pharmacol; 1996 Apr; 51(8):1003-8. PubMed ID: 8866821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
    Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
    Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
    Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
    Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.
    Murray S; Odupitan AO; Murray BP; Boobis AR; Edwards RJ
    Xenobiotica; 2001 Mar; 31(3):135-51. PubMed ID: 11465391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.